– USA, TX – Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D., to its Board of Directors. Dr. Magovčević-Liebisch is the executive vice president, chief business officer of Ipsen, a global biopharmaceutical group focused on innovation and specialty care with medicines in oncology, neuroscience and rare diseases.
“Ivana’s breadth of experience comes from more than two decades of impressive legal, commercial, transactional and scientific work,” said Anthony G. Quinn, M.B Ch.B, Ph.D., interim chief executive officer of Aeglea. “She is a multitalented executive with particular expertise in the rare genetic disease and cancer therapeutic areas, and we are excited to have her join the Aeglea team.”
“I look forward to working with Aeglea during this important time as it advances both its lead development program, pegzilarginase, and its research pipeline of additional enzyme-based therapeutics,” said Dr. Magovčević-Liebisch.
Prior to joining Ipsen, Dr. Magovčević-Liebisch was the executive vice president, chief strategy and corporate development officer for Axcella Health Inc. Before that, she was a senior vice president and the head of global business development for Teva Pharmaceutical Industries, where she was responsible for the global transaction group supporting the company’s specialty and new therapeutic entity business, among other duties. From 2001 to 2013, Dr. Magovčević-Liebisch worked for Dyax Corp, rising to the positions of executive vice president and chief operating officer. During that time, she established the commercial infrastructure of the company’s first FDA-approved drug, Kalbitor®, for treatment of hereditary angioedema attacks. Dr. Magovčević-Liebisch is currently a member of the boards of Alivio Therapeutics and Applied Genetic Technologies Corporation. She also serves as a trustee of Suffolk University, and an overseer of the Boston Ballet, Boston Museum of Science and Beth Israel Deaconess Medical Center. Dr. Magovčević-Liebisch has a B.A. in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University Medical School and a J.D. High Technology law from Suffolk University Law School.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas.
For more information : http://www.aegleabio.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.